Metrics to compare | BLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.0x | −0.9x | −0.3x | |
PEG Ratio | 0.09 | 0.01 | 0.00 | |
Price/Book | 8.4x | 0.6x | 2.6x | |
Price / LTM Sales | 3.5x | 1.0x | 3.0x | |
Upside (Analyst Target) | - | 75.3% | 53.8% | |
Fair Value Upside | Unlock | 22.2% | 8.6% | Unlock |
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products under the Dr Watson brand. The Wholesale PCC/USA segment is involved in wholesale of patented Probiotics for gastrointestinal health and immunity. It also provides contract manufacturing services; and storage and distribution services. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited is headquartered in Sydney, Australia